"Complete resolution of clinical symptoms occurred within a few days after the initiation of treatment and was followed by normalization of acute-phase reactants, hematological parameters, and biochemical markers of systemic disease within the first three months. According to the already reported literature, the time to complete resolution of clinical activity varied from a few hours after the first injection up to two months of treatment, with most cases remitting within some days, while laboratory markers returned to normal subsequently within one week to two months [13-19]. In the two largest already published series of 15 and 8 patients, respectively, disease activity completely resolved in 60% and 90% of patients, respectively, whereas no efficacy was reported in 13% of patients in the first study [18,19]. "
[Show abstract][Hide abstract] ABSTRACT: To assess the efficacy and safety of the interleukin-1 receptor (IL-1R) inhibitor anakinra in adult patients with refractory Still's disease.
Twenty-five patients (13 males and 12 females, median age 32 years, median disease duration seven months) with Still's disease were treated with subcutaneous injections of anakinra (100 mg/day). Treatment was given as adjunct therapy in 16 patients and as standalone in 9 patients for a median time of 15 months (range 1.5-71). The clinical and laboratory parameters during follow-up were recorded.
In 84% of patients the clinical activity resolved completely within a few days (median time 0.2 months), and response was maintained until the last visit in all but one patient. A complete response of all disease-related symptoms (clinical and laboratory) occurred subsequently within a median time of three months in 80% of patients. A partial clinical and laboratory improvement was shown in 12% and 16% of patients, respectively. The Visualized Analogue Scale and Health Assessment Questionnaire scores significantly decreased during treatment. The proportion of patients achieving the American College of Rheumatology 20 (ACR20) score (20% improvement) was 82% at one month and improved to 100% at one year. The mean oral corticosteroid dose was significantly reduced at each visit. Anakinra was discontinued due to unresponsiveness in one patient and due to relapsing disease in another. Treatment was also withdrawn in three patients with severe skin reactions (urticaria). Seven patients experienced an infection during follow-up.
The rapid and sustained response in the majority of our patients encourages the use of anakinra in adults with Still's disease.
[Show abstract][Hide abstract] ABSTRACT: Der adulte Morbus Still (engl. „adult onset Still’s disease“, AOSD) mit einer Inzidenz zwischen 1 und 3 Fällen pro 1 Mio. Einwohner gehört zu den diagnostisch aufwendigsten Fiebererkrankungen. Das Fehlen von Biomarkern und seine Ähnlichkeit mit infektiösen, malignen und rheumatischen Erkrankungen führt häufig zu einer protrahierten Diagnose. Der vorliegende Beitrag soll daher versuchen, über den Kenntnisstand der klinisch relevanten Symptome, die Laborparameter für die Diagnostik des AOSD sowie die neuen Therapiemöglichkeiten eine Übersicht zu geben.
Zeitschrift für Rheumatologie 04/2012; 71(3). DOI:10.1007/s00393-011-0859-6 · 0.46 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Postal surveys of service use are likely to overestimate health service use and may also underestimate health needs in the population. A historical cohort study, using postal questionnaires and medical records, showed that non-respondents are registered at addresses in more-deprived wards, they are less likely to have attended a hospital diabetes clinic (38% vs 45%) and much less likely to have had a diabetes review in general practice (11% vs 26%). An analysis based on questionnaire respondents would only therefore both underestimate the level of material deprivation and overestimate the proportion receiving routine reviews in general practice in a population with a chronic condition.
Public Health 02/2001; 115(1):78-9. DOI:10.1038/sj/ph/1900730 · 1.48 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.